Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glenmark pharmaceuticals (malaysia) sdn. bhd. - apremilast -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glenmark pharmaceuticals (malaysia) sdn. bhd. - clotrimazole -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glenmark pharmaceuticals (malaysia) sdn. bhd. - clotrimazole -

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - zonisamide (unii: 459384h98v) (zonisamide - unii:459384h98v) - zonisamide 25 mg - zonisamide capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. zonisamide capsules are contraindicated in patients who have demonstrated hypersensitivity to sulfonamides or zonisamide. the abuse and dependence potential of zonisamide has not been evaluated in human studies (see warnings, cognitive/neuropsychiatric adverse events subsection). in a series of animal studies, zonisamide did not demonstrate abuse liability and dependence potential. monkeys did not self-administer zonisamide in a standard reinforcing paradigm. rats exposed to zonisamide did not exhibit signs of physical dependence of the cns-depressant type. rats did not generalize the effects of diazepam to zonisamide in a standard discrimination paradigm after training, suggesting that zonisamide does not have abuse potential of the benzodiazepine-cns depressant type.

European Union - English - EMA (European Medicines Agency)

glenmark arzneimittel gmbh - olanzapine - schizophrenia; bipolar disorder - psycholeptics - adultsolanzapine is indicated for the treatment of schizophrenia.olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.olanzapine is indicated for the treatment of moderate to severe manic episode. in patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

European Union - English - EMA (European Medicines Agency)

glenmark arzneimittel gmbh - olanzapine - schizophrenia; bipolar disorder - psycholeptics - adultsolanzapine is indicated for the treatment of schizophrenia.olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.olanzapine is indicated for the treatment of moderate to severe manic episode. in patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

Ireland - English - HPRA (Health Products Regulatory Authority)

glenmark pharmaceuticals europe limited - ropinirole hydrochloride - film coated tablet - 1 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

glenmark pharmaceuticals europe limited - ropinirole hydrochloride - film coated tablet - 0.5 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

glenmark pharmaceuticals europe limited - ropinirole hydrochloride - film coated tablet - 2 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

glenmark pharmaceuticals europe limited - ropinirole hydrochloride - film coated tablet - 0.25 milligram